Pacific Edge raised NZ$35.3m in a rights issue, which completed in early July. Funds are to be used mainly to provide cash for continued commercialisation of its Cxbladder diagnostics tests in its primary US market, as well as to fuel international expansion. The company also recently announced its first User Programme in South-East Asia with the completion of an agreement with Singaporean hospital Tan Tock Seng representing the start of its stated intent to capture the significant South- East Asian market. Pacific Edge also reported full-year results at the end of May, largely in line with our expectations.
